Human p53, unlike mouse p53, contains a polymorphic site at codon 72 in exon 4 encoding either an arginine amino acid (72R) or a proline residue (72P). The 72R form was shown to induce apoptosis better than the 72P form, partly owing to its ability to efficiently bind to the nuclear-export protein CRM1 and localize to the mitochondria. This polymorphism has also been associated with cancer predisposition and chemo-sensitivity. Further understanding of the in vivo significance of this polymorphism in carcinogenesis requires the generation of mouse models. We have thus evaluated if the polymorphism-specific effects of human p53 are retained in mouse cells. Though being transcriptionally active, both the human polymorphs were found to have lost their ability to differentially suppress growth and bind to CRM1 or MDM2 in mouse cells. Moreover, chimaeric proteins containing mouse exons 2-3 and human exons 4-11 have also lost the polymorphism-specific effects in human cells, suggesting that human exons 2-3 are important in regulating the polymorphism-specific effects. Furthermore, human p53 and the various chimaeric proteins were generally less effective in inhibiting growth of mouse cells compared to mouse p53, suggesting that mouse p53 is more potent than human p53 in suppressing growth, partly due to enhanced binding of MDM2 to human p53. The data together suggest that mouse cells may not provide an appropriate environment for the manifestation of the polymorphism-specific functional differences of human p53, and hence, cautions against the expression of fulllength or chimaeric p53 proteins in mice to study the effects of the polymorphism.
Introduction
p53 is probably the most critical tumour suppressor gene product that regulates carcinogenesis, and hence, is mutated in about half of all human cancers (Vogelstein et al., 2000; Vousden and Lu, 2002) . p53 activation results in cell-cycle arrest and apoptosis, processes that eventually inhibit growth of cells (Vogelstein et al., 2000; Vousden and Lu, 2002) . Apoptosis induction by p53 involves both transactivation-dependent and -independent mechanisms (Erster and Moll, 2005; Schuler and Green, 2005; Yu and Zhang, 2005) . The latter can be accomplished by several means, and the mechanisms are beginning to be understood (Erster and Moll, 2005; Schuler and Green, 2005) . One region of p53 that regulates transactivation-independent cell death is the poly-proline region that was shown to be essential for apoptosis but not for cell-cycle arrest (Walker and Levine, 1996; Sakamuro et al., 1997; Baptiste et al., 2002) . This region also contains the common polymorphic site that is found only in human p53 (as opposed to p53 from mouse or other lower organisms), and encodes for an arginine residue or a proline residue at codon 72 (referred to as 72R or 72P) (Harris et al., 1986; Matlashewski et al., 1987; Buchman et al., 1988) .
Recent studies have shown that the 72R form is more potent in its ability to induce apoptosis compared to the 72P form, partly due to its ability to efficiently bind to the nuclear-export protein CRM1, which results in efficient mitochondrial localization (Dumont et al., 2003) . Consistent with these findings, clinical data indicate that head and neck cancer (HNC) cells expressing the wild-type 72R variant were more sensitive to a variety of anti-cancer drugs and these HNC patients had a longer survival compared to their 72P-expressing counterparts (Bergamaschi et al., 2003) , suggesting that the status of the p53 codon 72 polymorphism could influence the outcome of cancer therapy. However, other biochemical analyses have demonstrated that mutant p53, when in the 72R form, is capable of binding to p73, the structural and functional homologue of p53, and inactivating it (Marin et al., 2000) . This property of mutant p53 to bind and neutralize p73-mediated apoptosis was enhanced when the p53 was in the 72R form compared to the 72P form (Marin et al., 2000) . This negative inhibitory effect was shown to be specific for mutant forms of p53, as wild-type p53 was shown not to be able to bind p73 (Di Como et al., 1999; Strano et al., 2000) . Supporting these biochemical evidence was clinical data demonstrating that clinical response following cisplatin-based chemotherapy for advanced HNC was influenced by this polymorphism, and cancers expressing 72R mutants were found to have lower response rates than those expressing the 72P mutants (Sullivan et al., 2004) . Thus, polymorphism at codon 72 of p53 can have opposing effects on response to therapy, depending on the mutation status of the gene (Bergamaschi et al., 2003; Sullivan et al., 2004) .
Besides influencing the response to cancer therapy, the codon 72 polymorphism has also been associated with cancer predisposition. Previous results indicated that the 72R variant is much more susceptible to degradation by the HPV E6 protein, hence possibly predisposing to cervical cancers (Storey et al., 1998) . However, the significance of the p53 codon 72 polymorphism had remained controversial in terms of cancer epidemiology, with significant association being observed in some cases and not in others in several types of cancers (Sja¨lander et al., 1996; Weston and Godbold, 1997; Papadakis et al., 2000) . Nonetheless, it is possible that the differences between various reports can reflect the populations that were analysed, as there are inherent differences in the relative prevalence of the polymorphic alleles in various populations (Beckman et al., 1994) . We had therefore re-analysed the role of the polymorphic alleles in cancer predisposition to investigate if the expression status, rather than the genotype, may show correlations with the disease status. Our recent data demonstrated that there is a selective pressure against the expression of the 72R allele in healthy Asian individuals . However, the 72R allele was activated and hence selectively expressed in heterozygote breast cancer patients, suggesting that the 72R allele may predispose to certain cancer types .
Although the prevailing data suggest an important role for the codon 72 polymorphism in cancer predisposition, clinical data are at best correlative and do not provide clues as to whether the effects are causal or consequent. Because mouse p53 does not carry this polymorphism, generation of genetically modified mouse models expressing the various polymorphs may be able to address the in vivo significance of this polymorphism in carcinogenesis. However, before embarking on the laborious generation of genetically modified mice, we have evaluated the functional significance of the human polymorphs in different mouse cell types in culture. Our results indicate that the human codon 72 polymorphism-specific effects may not be manifested in the mouse cellular environment, and highlights the differences between human and mouse systems with respect to studying p53 biology.
Results

Generation of human-mouse p53 chimaeric constructs
We generated a series of chimaeric human/mouse p53 expression constructs for this study. As the codon 72 polymorphism is found in exon 4 of human p53, and as the 'human-p53 knock-in' (Hupki) mouse containing the human exons 4-9 in the mouse p53 locus is already available (Luo et al., 2001) , we generated chimaeric cDNA constructs that contained human exons 4-9 or 4-11, in either the 72R or 72P form (Figure 1a and b) . In these chimaeric proteins, exon 2, which contains the p53 start codon, and exon 3 were from mouse p53. All the chimaeric proteins were compared with human wild-type 72R or 72P proteins as well as wild-type mouse p53 protein. All constructs were sequenced for verification before use. Transient transfection of the various constructs together with a plasmid encoding the green fluorescent protein (eGFP), which served as a control for transfection efficiency, into the p53 null human H1299 cells resulted in the efficient and approximately equal expression of all chimaeric proteins ( Figure 1c ). As noted in previous studies (Thomas et al., 1999) , 72R polymorphic variant migrated faster than the 72P form, even when in the chimaeric form (Figure 1c ), indicating that the chimaerism has not altered this biochemical property of the polymorphs.
Chimaeric proteins retain transactivation property in human and mouse cells
The transactivation property of all p53 variants was next analysed using promoter-reporter constructs in transient transfection assays. To this end, all experiments were performed in both human (H1299) and mouse (p53 null mouse embryonic fibroblasts (MEFs)) cells with several p53-dependent target gene promoters. All chimaeric proteins were found to be transcriptionally active on all promoters in both cell types, albeit to different extents (Figure 2a and b) . Mouse and human p53 were equally active in human cells. However, mouse p53 was more active than human p53 (both 72R and 72P) in mouse cells on the AIP-1 promoter, and opposite results were observed on p21 promoter (Figure 2b ). Immunoblot analysis indicated that all the p53 constructs were expressed efficiently, thereby suggesting that differences in transfection efficiencies would not have contributed to the different transactivation potential (Figure 2a and b, lower panels). The ability of the constructs to activate endogenous target genes was next analysed by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) subsequent to transient transfection, in both human and mouse cells. All constructs were able to activate p21, noxa and Pig3 genes in human cells (Figure 2c , left panel). 72R appeared to be more active than 72P in activating noxa and Pig3, whereas mouse p53 was slightly weaker in its ability to transactivate these genes ( Figure 2c , left panel). All constructs were also able to activate noxa, bax and mdm2 to similar levels in mouse cells (Figure 2c, right panel) . Together, the data indicate that chimaeric proteins have not lost their potential to regulate target gene expression in both human and mouse cells, and that both human and mouse p53 proteins are capable of transactivating target genes in both cell types.
Comparison of the ability of mouse and human p53 to induce cell-cycle arrest in human and mouse cells The ability of the various p53 constructs to suppress growth was next analysed by either evaluating the effect of their expression on transient cell-cycle arrest or in long-term colony forming assays, which are able to reflect the potential of the expressed proteins to suppress cellular growth. All constructs were transfected into p53 null mouse MEFs or human H1299 cells, and cells were cultured and analysed for their ability to arrest at G 0 /G 1 phase of the cell cycle by flow cytometric analysis. Cells were then stained with anti-p53 antibody after fixation and only the transfected cells that were p53 þ were analysed, to exclude untransfected cells (data not Chimaeric constructs were generated using mouse p53 (exons 2-3) and either human p53 exons 4-9 or 4-11 (72R or 72P). In the former, exons 10 and 11 were from mouse p53. All cDNAs were cloned into pcDNA-based expression vector by standard molecular biology techniques. * Indicates position of codon 72 polymorphism. Filled bar: mouse p53 (mp53); open bar: human 72P; hatched bar: human 72R. (c) Steady-state expression of various constructs. All the constructs (0.5 mg) were transfected into H1299 cells together with the plasmid eGFP (0.1 mg), which was used to monitor transfection efficiency. Whole cell extracts were prepared and immunoblotted to determine p53 levels (using mixture of CM1 and CM-5 antibodies, which recognize human and mouse p53, respectively) and anti-eGFP antibody.
Loss of codon 72 polymorphism-specific effects in mouse cells BH Phang and K Sabapathy shown). eGFP and empty vector were transfected as negative controls and eGFP þ cells were analysed in this case. The results indicated that transfection of mouse p53 led to a marked increase of cells in G 0 /G 1 phase, resulting in about 73% of MEFs and 79% of H1299 cells being arrested at this stage, compared to vectortransfected populations in which only about 43-57% of the cells were in this phase of the cell cycle (Table 1) . Both 72P and 72R human p53 also caused similar cellcycle arrest in both cell lines. However, the efficiency of human p53 (72R or 72P)-mediated arrest was not as that observed with mouse p53. There was also a tendency for 72P to arrest cells to a slightly higher extent than 72R in both mouse and human cells (72R: 53% (MEFs) and 61% (H1299); 72P: 63% (MEFs) and 73% (H1299)) (Table 1) , consistent with earlier findings (Pim and Banks, 2004) . All the chimaeric proteins were able to induce cell-cycle arrest in mouse and human cells, and there were no differences between the 72R or 72P forms (Table 1) . Together, the data suggest that although both mouse and human p53 were capable of inducing cell-cycle arrest in mouse and human cells, mouse p53 was more potent in both these cell types.
Mouse p53 is generally more potent than human p53 in suppressing growth and the polymorphism-specific effects are not observed in mouse cells We next evaluated the ability of the p53 proteins to induce long-term growth suppression, in colony formation assays, by transfecting the expression constructs into p53 null human SAOS2 cells and p53 null MEFs and selected them with antibiotics for about 2 weeks. As shown in Figure 3a , both 72R and 72P human p53 suppressed growth, as there were much fewer colonies compared to vector-transfected SAOS2 cells. However, expression of 72R resulted in fewer colonies compared to 72P expression (number of colonies -vector: 397; 72R: 64; 72P: 106; 72R vs 72P: P ¼ 0.0185), indicating that 72R has the potential to inhibit growth better than 72P, consistent with previous reports (Dumont et al., 2003) . Moreover, mouse p53 was found to inhibit growth of human cells much better than human p53 (number of colonies -mouse p53: 44) (72R vs mouse p53: P ¼ 0.037; 72P vs mouse p53: P ¼ 0.035) (Figure 3a) , suggesting that mouse p53 may be more potent than human p53 in its function. Comparison of MEFs (right panel), as described above, was determined by RT-PCR. Endogenous gapdh RNA level was determined as loading control. Loss of codon 72 polymorphism-specific effects in mouse cells BH Phang and K Sabapathy the chimaeric proteins revealed that all chimaeric proteins were able to inhibit growth, and were even more potent than full-length human p53 in doing so (number of colonies-4-9(72R): 28; 4-9(72P): 16; 4-11(72R): 25; 4-11(72P): 6) (Figure 3a) , indicating that the presence of mouse p53 elements (exons 2-3) conferred greater growth suppressive properties to the chimaeric proteins. In addition, the effect of the codon 72 polymorphism was not evident in the chimaeric proteins, as the expression of the 72R chimaeric proteins did not result in enhanced growth suppressive effects compared to the 72P chimaeric proteins (Figure 3a) , suggesting that the presence of human exons 2-3 (and not mouse) may be necessary for the differential effects of the codon 72 polymorphs in human cells. Analysis of growth suppression in mouse MEFs indicated that in contrast to mouse p53, human p53 was not able to significantly suppress cellular growth (number of colonies-vector: 210; 72R: 160; 72P: 148; mp53: 87) (72R vs mouse p53: P ¼ 0.00005; 72P vs mouse p53: P ¼ 0.038) (Figure 3b) . Moreover, the polymorphism-dependent effect on growth observed in human cells was also not evident in mouse cells (72R vs 72P: P ¼ 0.1019). These results were consistently reproducible in several experiments, suggesting that the codon 72-specific effects of human p53 may be specific to human cells. Furthermore, chimaeric proteins were also not as potent as the mouse p53 protein in their ability to suppress growth (number of colonies-mp53: 87; 4-9(72R): 169; 4-9(72P): 154: 4-11(72R): 138; 4-11(72P): 137) (Figure 3b) , suggesting that the presence of human exons in chimaeric proteins might compromise the ability to inhibit growth in mouse cells. We hypothesized that human p53 may be more sensitive to mouse MDM2 compared to mouse p53, as suggested by Dudgeon et al. (2006) , thereby leading to the reduced ability of human p53 in inhibiting colony formation in mouse cells. To address this possibility, we repeated the colony formation experiments in mouse p53
MEFs (as well as p53
À/À MEFs). Transfection of human and mouse p53 indeed resulted in much lesser colonies when compared to the transfection in p53 À/À MEFs (number of colonies-vector: 140; 72R: 50; 72P: 55; mp53: 24) (Figure 3c , and data not shown), suggesting were transfected with the indicated plasmids (0.5 mg) and cells were selected for 2 weeks on 1 mg/ml neomycin (SAOS2) or 2.0 mg/ml puromycin (MEFs and ES cells were also co-transfected with 0.1 mg puromycin resistance plasmid). Cells were stained for colony formation. All experiments were performed at least thrice independently and colonies were counted both manually and using colony count software. Similar results were obtained using both methods. Data are presented as the mean7s.d. error of the mean.
Loss of codon 72 polymorphism-specific effects in mouse cells BH Phang and K Sabapathy that the absence of MDM2 indeed allowed the transfected p53 to inhibit colony formation much better. However, even in these cells, expression of mouse p53 resulted in much lesser colonies compared to expression of human 72R or 72P, indicating that human p53 is less efficient in mouse cells independent of the MDM2 status. In order to evaluate if the absence of human codon 72-specific polymorphic effects noted in p53 À/À MEFs is also observed in other cell types, we repeated the colony formation assays in p53 À/À pluripotent embryonic stem (ES) cells (Sabapathy et al., 1997) . Although both human and mouse p53 were able to suppress colony formation in these cells, there were no significant differences noted between the 72R and 72P forms of human p53 and between human and mouse p53 (number of colonies-vector: 61; 72R: 38; 72P: 39; mp53: 37) (Figure 3d ). In addition, the 72R-specific effects were also not observed with the chimaeric proteins, which were also able to suppress growth to approximately similar extents to mouse p53 (number of colonies-mp53: 37; 4-9(72R): 34; 4-9(72P): 26; 4-11(72R): 24; 4-11(72P): 21) (Figure 3d ).
Taken together, the data suggest that mouse p53 is generally more potent in its ability to inhibit growth of human and mouse cells and that human p53 is less effective in inhibiting growth of mouse MEFs. Moreover, the codon 72-specific effects on growth suppression are seen only in human cells and appear to be dependent on the presence of human exons 2 and 3.
p53 polymorphs do not show differential binding to CRM1 and MDM2 in mouse cells As the polymorphism-specific effects on growth suppression was not observed in mouse cells, and as the 72R variant of human p53 was shown to associate with the nuclear-export protein CRM1 better than the 72P form -thereby being efficiently transported to mitochondria (Dumont et al., 2003) -we evaluated if CRM1 binding is differentially affected in human and mouse cells. To this end, we transfected cells with the various p53 constructs and immunoprecipitated the endogenous CRM1 protein from total cell lysates. Immunoblotting of the immunoprecipitates with anti-p53 antibodies indicated that more 72R was bound to CRM1 than 72P in human cells (Figure 4a , compare lanes 2-3 and 5-6), consistent with previous findings (Dumont et al., 2003) . We had used two human cellular systems, namely the H1299 cells, which stably express the temperature-sensitive human p53 polymorphs (lanes 1-3) (Siddique and Sabapathy, 2006) , and the p53 null SAOS2 cells in which the p53 expression constructs were transiently transfected (lanes 4-6), and found similar results in both cases (Figure 4a ). However, both 72R and 72P forms were bound equally to CRM1 in p53 null MEFs (Figure 4a , compare lanes 8-9), indicating that preferential binding of 72R to CRM1 is perhaps specific to the human cellular environment. We have excluded the differences in expression of these proteins in these cells, as direct immunoblots indicated that both the polymorphic variants were expressed to equal extents in all cell lines (Figure 4a, lowest panel) . We further evaluated the ability of the different polymorphs to bind to MDM2 in mouse cells, as it was suggested that the 72R form had a À/À MEFs were transfected as described in Figure 1 . H1299 cells expressing temperature-sensitive (ts) p53 (72R or 72P) and cultured at 371C were also used. Total cell lysates (300 mg) was immunoprecipitated with anti-CRM1 (a) or anti-MDM2 (b) antibodies, and subsequently immunoblotted with anti-p53 (Pab 240) and anti-CRM1 or anti-MDM2 antibodies. Total cell lysates were also detected by straight immunoblotting to determine amount of p53 in each cell line (a -lowest panel). (c) p53 À/À MEFs were transfected with the various constructs as indicated and immunoprecipitated with anti-CRM1 or anti-MDM2 antibodies as described. Immunoblot analysis was performed as described above. higher affinity for MDM2 than the 72P form (Dumont et al., 2003) . Immunoprecipitation of MDM2 from the indicated cell lines followed by immunoblotting with anti-p53 antibodies indicated that the 72R variant had a slightly higher affinity for MDM2 in both the human cells lines, consistent with the previous report (Figure 4b , compare lanes 2-3 and 5-6). However, both the human p53 variants were bound to equal extents to mouse MDM2 (Figure 4b, compare lanes 8-9) , suggesting that the preferential binding to MDM2 by the 72R variant might again be specific to the human cellular environment.
As the polymorphism-specific effects were not seen in mouse cells and as human p53 was not able to efficiently suppress growth compared to mouse p53 in p53 À/À MEFs, we compared the binding of the various p53 constructs to CRM1 and MDM2 in p53 À/À MEFs. Immunoprecipitation of CRM1 indicated that human p53 (both 72R and 72P) were bound to similar extends to mouse p53 (compare lanes 1 and 2-3), and all the chimaeric proteins were less bound to CRM1, though to varying degrees (lanes 4-7) (Figure 4c ). There was a tendency for 4-9(72R) to be slightly more bound to CRM1 than 4-9(72P), though the levels did not reach that of full-length 72R or 72P (Figure 4c) . Strikingly, however, immunoprecipitation of MDM2 indicated that mouse p53 was bound much less compared to human p53 (both 72R and 72P) to MDM2 in MEFs (compare lanes 8-9 and 10, Figure 4c ). These results were consistently reproducible and supported the notion that increased binding of human p53 compared with mouse p53 to MDM2 in MEFs may neutralize human p53 effects, hence leading to the observed reduced growth suppressive properties of human p53. Moreover, the polymorphism-specific effects were not seen in the chimaeric proteins that were also more bound to MDM2 compared to mouse p53 (lanes 11-14, Figure 4c) .
These data together demonstrate that although the 72R variant has a higher affinity for CRM1 and MDM2 in human cells compared to 72P, this may not always be the case in the mouse cellular environment. In addition, MDM2 in mouse cells appear to have a higher affinity for human p53 compared to mouse p53, which may lead to enhanced inactivation of human p53 function in mouse cells. These data therefore highlight the biochemical differences of the human polymorphic variants in the mouse cellular environment as well as the differences between mouse and human p53 with respect to MDM2 binding.
Discussion
The data presented here highlight several interesting findings that are relevant to the study of p53 function: (i) mouse p53 is generally more potent than human p53 in its ability to induce growth arrest in both human and mouse cells; (ii) the codon 72 polymorphism-specific effects of human p53 observed in human cells are not recapitulated in the mouse cellular environment and (iii) the codon 72-specific effects of human p53 appear to be dependent on the amino-terminal exons 2-3 of p53.
Although both mouse and human p53 constructs have the ability to induce growth arrest and have been used inter-changeably in both cellular systems, we believe that direct comparisons on their ability to affect physiological changes have not been made. It was thus interesting to note that mouse p53 was more potent than human p53 in its ability to induce both transient cellcycle arrest and long-term growth suppression. We believe that these findings are physiologically relevant and are not due to cell-culture effects. In support of this, recent reports from others and us suggest that the human p53 protein may not be as efficient as mouse p53 in inhibiting tumour formation in vivo (Dudgeon et al., 2006; Tong et al., 2006) . Transgenic mice expressing human p53 in the p53-null background did not prevent accelerated tumour development after genotoxic or oncogenic stress, owing to enhanced binding of mouse MDM2 to human p53 (Dudgeon et al., 2006) . Similarly, mice expressing the human-mouse chimaeric p53 protein (Hupki mice) were more susceptible to aflatoxinb 1 -induced liver cancer formation compared to wildtype mice (Tong et al., 2006) , although the same mice did not show differences compared to wild-type mice in another model of N-nitrodiethylamine-induced liver tumorigenesis (Jaworski et al., 2005) . Thus, many of these in vivo studies are consistent with our in vitro findings that human p53 may not be as potent as mouse p53 in its function as a tumour suppressor.
There are several explanations for the reduced potency of human p53 or the enhanced effect of mouse p53. In the first instance, HDM2 in human cells may have less affinity for mouse p53, thereby leading to reduced degradation of the latter, and hence, its enhanced biological effects. Indirect support for this comes from the 4-11 chimaeric proteins -that contained only mouse exons 2 and 3 -which were capable of inducing a strong long-term growth arrest effect comparable to mouse p53 in human cells. On the contrary, human p53 may be more efficiently bound to mouse MDM2 in mouse cells, thereby being more effectively degraded, hence resulting in its reduced efficiency in inducing growth arrest. Our immunoprecipitation results support this hypothesis as human p53 was found to be efficiently bound to MDM2 compared to mouse p53 (Figure 4c ). Furthermore, recent data from Dudgeon et al. (2006) also indicated that mouse MDM2 has a higher affinity for human p53, and inhibition of this binding using nutlin relieved the suppressive effects and resulted in the activation of human p53. However, it is to be noted that human p53 was not less effective than mouse p53 in ES cells, which are peculiar due to the high levels of endogenous p53 in these cells (Sabapathy et al., 1997) . Notwithstanding the ES cells, our results using mdm2
À/À MEFs also indicated that although lack of MDM2 enhanced human p53's ability to induce long-term growth arrest, human p53 was still less effective than mouse p53 in these cells. This suggests that there may be other factors that may also affect the potency of human p53 in mouse cells. One possibility is that post-translational modifications such as phosphorylation at the amino terminal may be differentially affected in mouse cells (Jardine et al., 1999) . Moreover, results from the 4-9 p53 chimaeric constructs indicated that the presence of human DNA-binding domain (exons 4-9) is sufficient enough to weaken the chimaeric protein's ability to induce growth arrest in mouse cells. This suggests that the human p53 may have reduced ability to bind mouse DNA, and hence induce target genes. However, analysis of the transcriptional ability of the chimaeric proteins to activate several p53 target gene promoter-reporter constructs or endogenous target genes do not support this idea, as there were no significant differences between the chimaeric proteins and mouse p53 in MEFs (Figure 2) . Hence, one possibility is that human p53 may be less efficient in other transcription-independent activities than mouse p53. These possibilities require further investigations. Nonetheless, it is evident from the presented data that human p53 is less effective than mouse p53 in inducing growth arrest.
The data that MDM2 efficiently binds to human p53 and thereby probably affects its function suggests that the levels of p53 may be critical in dictating the physiological outcome. They are many reports that support this notion. Firstly, haploinsufficiency effects were observed in cells from the p53 þ /À mice and the opposite effect was observed from mice carrying the hypomorphic mdm2 allele (Harvey et al., 1993; Mendrysa et al., 2003 Mendrysa et al., , 2006 . Cells from these mice were shown to have reduced or elevated p53 levels, which consistently affected proliferation and apoptotic rates accordingly. Moreover, p53 haploinsufficieny affected tumorigeneic rates and the mdm2 hypomorphic mice were more resistant to tumours (Venkatachalam et al., 2001; Mendrysa et al., 2003) . Secondly, although transient transfection studies such as those presented here have inherent limitations, the amount of transfected p53 was also shown by other investigators to correlate with the extent of its function, in many systems, including direct transfection of p53 alone, in combination with Mdm2 or Epstein-Barr virus-infection, in response to drug treatment or in cells that inducibly express varying amounts of p53 (Chen et al., 1996 (Chen et al., , 1998 Haupt et al., 1996; Rowan et al., 1996) . Thus, it is evident that the levels of p53 in the cell can regulate the extent of its function, as is seen with human and mouse p53 in the MEFs.
Another salient feature that is apparent from this study is that the codon 72-specific polymorphic effects are essentially lost in the mouse cellular environment. Biological and biochemical differences were reported between 72R and 72P in human cells (Dumont et al., 2003; Pim and Banks, 2004) , which were also seen in our experiments with human cells. However, both the biological and biochemical differences were either not observed or were reduced in mouse cells in similar experiments, indicating that the mouse cellular environment may not be apt for the polymorphism-specific effects of human p53. The 4-9 p53 chimaeric proteins that contained only the human DNA-binding domain and the amino-and carboxyl-terminal domains from mouse p53 were also not capable of exhibiting polymorphism-specific effects in mouse cells, although all chimaeric proteins had similar abilities to activate transcription of target genes. These data together suggest that exhibition of human p53 polymorphismspecific properties in mouse cells may not require transcriptional differences but may require factors that may be found only in human cells, and cautions against the study of codon 72 polymorphism in the mouse context. In this respect, it is noteworthy that the Hupki mice, which expresses the 72R polymorph (i.e. 4-9[72R]) (Luo et al., 2001) , or an equivalent 4-9(72P) model may not be good experimental tools to study the specific effects of codon 72 polymorphs, and efforts along these lines should be carefully evaluated.
Finally, it is evident from the study of chimaeric proteins that human exons 2-3 are probably required for the manifestation of the polymorphism-specific effects of human p53. All chimaeric proteins used in this study did not exhibit polymorph-specific effects on short-or long-term growth arrest in human cells, unlike full-length human p53. This indicates that the aminoterminal portion of human p53 may influence its function, with respect to codon 72 polymorphism. The amino-terminal exons contain the MDM2 binding site, as well as several phosphorylation sites. Although the role of phosphorylation on polymorphism-specific effects is not well established, MDM2 was shown to preferentially bind to 72R (Dumont et al., 2003) . In this respect, it was suggested that greater binding and ubiquitination of 72R by MDM2 leads to greater nuclear export, enhanced mitochondrial localization and hence, greater ability to induce apoptosis (Dumont et al., 2003) . Thus, our results are consistent and support the idea that efficient MDM2 binding may be required for the codon polymorphism-specific effects in human cells.
In conclusion, the data presented here demonstrates that codon 72-specific effects of human p53 are not exhibited in the mouse cellular environment and that human p53 appears to be generally weaker than mouse p53 in its growth suppressive functions in both mouse and human cells. These data therefore raises concern over the use of human p53 constructs in mouse cells/ models (e.g. MEFs, ES cells) to explore their biological properties, and suggest that such approaches may therefore not be ideal for the study of the physiological properties of the human protein. Caution should therefore be exercised before embarking on generation of mice models to study specific effects of human p53, such as the codon 72-specific polymorphism effects. were used in this study. All cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% foetal calf serum (Hyclone) in the presence of 5% CO 2 at 371C, as described (Vikhanskaya et al., 2005) . ES cells were cultured in the presence of leukemia inhibitory factor (LIF), as described . H1299 cells expressing the temperature sensitive human p53 have been described (Siddique and Sabapathy, 2006) .
Materials and methods
Cell
Generation of chimaeric constructs
Human 72R and 72P p53 cDNA and mouse p53 cDNA have been described Siddique and Sabapathy, 2006) , and were cloned into pcDNA3 via HindIII and NotI, respectively. To generate chimaeric constructs, mouse p53 plasmid was digested with EcoRV and SacII to release a partial fragment starting from the middle of exon 2 to the end of exon 9 of mouse p53. PCR using primer pair (i) and (ii) was performed using the human p53 cDNA construct to generate human p53 from exon 4-9 (72R or 72P) (902 bp). This fragment was then cloned into the digested mouse p53 plasmid to yield a plasmid termed as construct A. Construct A was then digested with HindIII and EcoRV to excise the remaining partial mouse exon 2 till the junction before human exon 4. The mouse exons 2-3 were then inserted back into this construct in-frame by using an adaptor, which was generated using primer pair (v) and (vi), resulting in the product termed as construct B (4-9)(72R or 72P). Construct B was then digested with SacII and NotI to excise out the entire mouse exons 10-11. PCR using primer pairs (iii) and (iv) and human p53 as a template generated human p53 from exon 10-11 (187 bp). This PCR product was then cloned into the digested construct B and produced a construct C (4-11)(72R or 72P). All constructs were sequenced to verify that there were no additional mutations and that the junctions were in frame, before further use. The schematic of the construct generation is depicted in Figure 1a .
Primers used in cloning: (i) EcoRV Hu ex4 forward: 5 0 -gata tcctgtcccccttgccgtcc-3 0 ; (ii) SacII Hu ex9 reverse: 5 0 -ccgccgatct gaagggtgaaa-3 0 ; (iii) SacII Hu ex9 forward: 5 0 -cagatccgcgggcgt gag-3 0 ; (iv) NotI Hu ex11 reverse: 5 0 -gcggccgctcagtctgagtcaggc 3 0 ; (v) forward: 5 0 Phosp-atgactgccatggaggagtcacagtcggatat cagcctcgagctccctctgagccaggagacattttcaggcttatggaaactccttcctcc agaagat-3 0 ; (vi) reverse: Phosp-atcttctggaggaaggagtttccataag cctgaaaatgtctcctggctcagagggagctcgaggctgatatccgactgtgactcctc catggcagtcat-3 0 Luciferase assays Transfections were carried out using Lipofectamine Plus reagent as per the manufacturer's description, using 0.5 mg of the various p53 plasmids as indicated and 0.5 mg each of the indicated luciferase reporter plasmid, and 0.1 mg the plasmid encoding the b-galactosidase gene for evaluating the transfection efficiency. The following pGL3 basic vector based (Promega, Madison, WI, USA) Trp53 responsive promoter reporter constructs were used in this study: gadd45-luc and p21-luc, mdm2-luc and p53AIP-1-luc. Cells were generally collected 48-h post-transfection and luciferase assays were performed in triplicates, as described (Toh et al., 2005) . All experiments were performed in triplicates, and at least three independent times and representative results are shown. Half of the samples were used for immunoblotting to evaluate the expression status of the transfected plasmids.
Western blot and immunoprecipitation analysis Cells were collected 48 h after transfection and total cell lysates were prepared in sodium dodecylsulphate (SDS) lysis buffer as described . Thirty micrograms of lysate was loaded on SDS gel and separated by electrophoresis on a 10% acrylamide gel. Gels were transferred onto blots by Western blotting and immuno-detected with antibodies to p53 (mixture of CM1 and CM-5, which recognizes human and mouse p53, respectively), eGFP (FL, Santa Cruz, Santa Cruz, CA, USA), anti-CRM1 (Santa Cruz, H-300), anti-MDM2 (Santa Cruz, SMP14) and anti-actin (A-2066, Sigma, St Louis, MO, USA).
Immunoprecipitations were carried out using anti-CRM1 and anti-MDM2 antibodies and 300 mg of lysate. Immunoprecipitates were resolved by electrophoresis and immunoblotted with anti-p53 (clone Pab 240, Calbiochem, Frankfurt, Darmstadt, Germany), anti-CRM1 (H-300) and anti-MDM2 (SMP14) antibodies. Total cell lysates were also detected by straight immunoblotting to determine amount of p53 in each cell line RNA and semiquantitative RT-PCR Total RNA was extracted from cultured cell lines using Trizol reagent (Invitrogen, Carlsbad, CA, USA), as per the manufacturer's instructions, 48 h after transfection. Total RNA was reverse transcribed to first-strand cDNA, 1 ml of which was used as a template for quantitative PCR, subsequent to optimization of the number of PCR cycles, annealing temperature and extension time, for each gene. PCR reactions were carried out using the MJ Thermal Cycler (PTC-100) as follows: 941C for 3 min followed by 941C for 30 s, 551C for 30 s and 721C for 30 s, continuing for 28 cycles for Noxa, Bax, Pig3 and MDM2. Amplification of gapdh was carried out at 22 cycles.
The following primers were used -for H1299 cells -gapdh: Flow cytometric analyses p53 null human H1299and p53 À/À MEFs were transfected with the indicated plasmids (0.5mg) and cells were harvested 48 h post-transfection. Simultaneous staining of intracellular p53 (with Pab 246 primary antibody and fluorescein isothiocyanate-conjugated anti-mouse immunoglobulin (Ig)G antibody) and genomic DNA (by propidium iodide) was performed as described (Haupt et al., 1995) and the cells were analysed by flow cytometry with FACSCalibra (BD Biosciences, San Jose CA, USA). p53 expressing cells, which emitted green fluorescence, were gated (except for vector transfected controls) and their cell-cycle profile was determined by ModFIT cell-cycle analysis software (BD Biosciences). Vector transfected cells were transfected with an eGFP plasmid and eGFP þ cells were gated in this case for analysis. All experiments were performed in duplicates and at least twice independently.
Colony formation assays
The following cells were used for colony formation assays: p53 null human SAOS2 cells, p53 À/À or p53 1 day before transfection. All cells were transfected with the indicated plasmids (0.5 mg) and cells were selected for 2 weeks on 1 mg/ml neomycin (SAOS2) or 2.0 mg/ml puromycin (MEFs and ES cells were also co-transfected with 0.1 mg puromycin resistance plasmid). Cells were stained with Gram's crystal violet solution (Merck) for visualization of colonies. All experiments were performed at least thrice independently and colonies were both counted manually and using colony count software. Similar results were obtained using both methods. Data are presented as the mean7s.d. error of the mean.
Statistical analysis
Student's t-test was used to test for statistical significance of the differences between the different group parameters (between 72R and 72P vs mouse p53). P-values of less than 0.05 were considered statistically significant.
